Abstract: Disclosed in the present invention is a synthesis method for high-purity cholesterol. The cholesterol is synthesized by using plant-derived 21-hydroxy-20-methylpregn-4-en-3-one, which is also referred to as bisnoralcohol or BA, as a raw material, and by means of steps of oxidation, Wittig reaction, acetylation, reduction, hydroxyl protection, selective hydrogenation reduction, and deprotection or hydrolysis reaction, and the purity can reach 99% or above. Aiming at defects of conventional animal-derived cholesterol, in the present invention, the cholesterol is synthesized from plant-derived raw material BA; thus, high safety is achieved, the risk of pathogenic bacteria and virus infection is avoided, high synthesis yield, high product purity, and environmental friendliness are achieved, and industrial production is facilitated.

Abstract: A helper epitope peptide is obtained by means of replacing one or two amino acid residues in the helper T cell epitope PADRE with 4-nitrophenylalanine. The helper epitope peptide is effective for enhancing the immunogenicity of an antigen or antigenic epitope or for preparing or constructing a vaccine, and a fusion antigen formed by connecting the helper epitope peptide to an antigen or an antigenic epitope.

Abstract: The present invention belongs to the field of medicinal chemistry, and particularly relates to synthesis, a preparation method and the use of an inhibitor containing dual targets SHP2 and CDK4/6, wherein the inhibitor comprises three compounds of general formulas I-III and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs or prodrugs thereof. According to the present invention, a class of brand-new SHP2 and CDK4/6 dual-target inhibitors are prepared by means of a pharmacophore fusion and reasonable drug design method, so that the problems of drug resistance, poor drug effect, etc., of the existing SHP2 inhibitor and CDK4/6 inhibitor are solved; the great significance of the present invention is providing the first SHP2 and CDK4/6 dual-target inhibitor, which provides a basis for solving the problem of drug resistance of kinase and phosphatase in the later period.

Abstract: A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they als show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

Abstract: A cosmetic composition containing ?-mangostin, and use thereof are disclosed. The cosmetic composition includes ?-mangostin and a sunscreen agent. The ?-mangostin is a pure ?-mangostin or an ?-mangostin-containing extract. The sunscreen agent is an inorganic sunscreen agent or an organic sunscreen agent. Herein, the inorganic sunscreen agent is one or more selected from a group of zinc oxide and titanium dioxide. The organic sunscreen agent is a sunscreen agent having a sun protection wavelength range that can be complementary to that of the ?-mangostin or a sunscreen agent that is easily decomposed or easily oxidized under UV exposure. The organic sunscreen agent is one or more selected from a group of butyl methoxydibenzoylmethane, octocrilene, ethylhexyl salicylate, octyl salicylate, homosalate, ethylhexyl methoxycinnamate and terephthalylidene dicamphor sulfonic acid.

Abstract: A series of 3-hydroxy-5-(isoxazol-5-yl) pyridine formylglycine compounds, a preparation method, a pharmaceutical composition, and the use. A structure of the compounds is shown as formula (I), and the compound derivatives comprise pharmaceutically acceptable salt thereof. The compounds and the pharmaceutical composition thereof have a high inhibition effect on HIF inhibition factors, and the activity can optimally reach the nano-molar concentration level, so that the compounds can be used for preparing a drug for treating fat metabolic diseases.

Abstract: Provided in the present invention is the use of an enhancer named as 3C1 in the preparation of an enhancer for the interaction between FXR protein and Caspase 8 protein. The enhancer can promote the interaction between FXR protein and Caspase 8 protein, thereby inhibiting the recruitment of Caspase 8 to apoptosome and blocking its formation, inhibiting the cleavage and activation of Caspase 8, blocking signal transduction of apoptosis, and ultimately inhibiting cell apoptosis. Therefore, the enhancer can be used for preparing a drug for treating liver diseases characterized with hepatocyte apoptosis.

Abstract: The present invention is related to compounds of formula I containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton and preparation methods therefor. It has been experimentally verified that the compounds containing a tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton have significant agonistic effects on caseinolytic protease P (ClpP), and can be applied in the treatment of various cancers.

Abstract: The invention discloses small molecular compounds targeting SRSF6 protein, its preparation method and applications. The compound is shown in formula (I). This molecule can selectively inhibit abnormal cells with high expression of SRSF6, thereby reducing the occurrence of abnormal alternative splicing events and inhibiting the occurrence and development of tumors, especially colorectal tumors. It can be used as a candidate new drug for anti-colorectal cancer.

Abstract: A cell-based sensor based on surface-enhanced Raman scattering and an application thereof. The cell-based sensor is established by guiding a surface-enhanced Raman scattering probe into a human liver cell line; the surface-enhanced Raman scattering probe is prepared by using a gold nanoparticle as a testing substrate, a gene damage effector molecule antibody as a recognition unit, a Raman molecule as a reporting unit, SH-PEG-NH2 as a stable chain and a cell-penetrating peptide as an auxiliary penetration unit; and the cell-based sensor is exposed to various drug impurities, a Raman signal is detected, and a type and a level of the genotoxic impurities are assessed.

Abstract: Cinnamoyl amino acid compounds and a use thereof, which relate to the fields of medicinal chemistry and pharmacotherapeutics, and specifically relate to cinnamoyl amino acid compounds having inducible nitric oxide synthase (iNOS) inhibitory activity or a pharmaceutically acceptable salt thereof, a pharmaceutical composition including the compounds, and a medical use thereof, particularly an application thereof in the prevention and treatment of neurodegenerative diseases related to nerve cell damage, including ischemic stroke, Parkinson's disease, and so on.

Abstract: A method for anchoring and modifying a nano-drug on the surface of a living cell includes: introducing an active reactive group to a living cell surface by a hydrophobic tail chain of a cell membrane anchoring molecule; modifying the nano-drug surface with a corresponding reactive group; and executing a biological orthogonal click reaction on the active reactive group modified on the living cell surface and the corresponding reactive group modified on the nano-drug surfae, to anchor and modify the nano-drug to the cell surface obtaining a living cell modified with the nano-drug. The method provides a new technical platform for cell modification and has very wide application prospects. Compared with pure cells and pure nano-drugs, a cell drug obtained by the above-mentioned cell modification technology has an optimal treatment effect and provides a new idea and a new drug for treating various diseases.

Abstract: The present disclosure relates to a pharmaceutical composition, including a first component and a second component, where the first component is selected from the group consisting of forskolin, isoforskolin, and a pharmaceutically acceptable salt thereof; and the second component is selected from the group consisting of a pentacyclic triterpenoid and a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present disclosure allows the combined use of forskolin-isoforskolin with a pentacyclic triterpenoid. Compared with the use of each of the two components alone, the combined use can play a significant synergistic role in prevention and treatment of a metabolic disease, a fibrotic disease, and a liver disease. Therefore, the pharmaceutical composition of the present disclosure has promising medicinal prospects in treatment, prevention, and improvement of obesity, a non-alcoholic fatty liver disease (NAFLD), liver damage, liver fibrosis, and the like.

Abstract: The present invention discloses a polypeptide and application thereof. By modifying oxyntomodulin (OXM), hybridizing OXM with a peptide sequence of Exenatide, including enabling the polypeptide to be resistant to DPP-4 enzyme degradation through amino acid modification, and conjugating fatty acid chains at the same time, an OXM hybrid peptide having longer pharmacologic action time and better weight losing effects is obtained. Synthesis of a target polypeptide is fast realized by an orthogonal protection strategy solid-phase synthesis method, and a crude product is purified and freeze-dried to obtain the OXM hybrid peptide.

Abstract: The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.

Abstract: A benzo[b]selenophene STING regulator, a preparation method therefore and use thereof are disclosed. The structure of the compound is shown in Formula I. A derivative, salt, stereoisomer, prodrug molecule and pharmaceutical composition of the present invention can serve as an immune regulator to effectively activate an innate immune regulation passageway to kill tumor cells.

Abstract: Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate Nrf2 to relieve inflammatory damage and improve an inflammatory microenvironment, has a potential anti-inflammatory activity, and can be used for preparing an anti-inflammatory drug for inflammatory damage of various inflammation-related diseases, including chronic obstructive pulmonary disease (COPD), Alzheimer's disease, Parkinson's disease, atherosclerosis, chronic kidney disease (CKD), diabetes, intestinal Inflammations, rheumatoid arthritis, etc.

Abstract: A hydroxamic acid-containing compound represented by formula I, and a preparation method, and a use thereof are provided. An inhibitory activity of the hydroxamic acid-containing compound on acid sphingomyelinase (ASM) is evaluated by a biological experiment. The compound is further subjected to in vivo pharmacodynamic investigation, and the results show that the compound exhibits significant anti-depression and anti-atherosclerosis (AS) activities, which provides feasibility for the further development of an ASM inhibitor.

Abstract: The present disclosure relates to the field of pharmaceutical chemistry, in particular to a class of PARP/PI3K double-target inhibitors (I) containing structures of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine and phthalazin-1(2H)-one and a preparation method thereof. As proved by pharmacodynamic tests, the compounds of the present disclosure have PARP/PI3K double-target inhibitory activity and can be used for anti-tumor.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.